Elementis PLC Directorate Change (2660C)

TIDMELM

RNS Number : 2660C

Elementis PLC

16 October 2020

16 October 2020

Elementis plc

Appointment of non-executive director

Elementis plc (ELM.L) (the "Company"), global specialty chemicals company, today announces the appointment of Christine Soden as a Non-Executive Director with effect from 1 November 2020. Christine will join the Audit, Nomination and Remuneration Committees and will serve as the designated non-executive director for workforce engagement.

Christine is an experienced CFO with a strong track record gained from leading a range of private and public companies rooted in innovation with a particular focus on biotechnology, life sciences and pharmaceutical products.

From 2015 until February 2020 she was CFO and Company Secretary of Acacia Pharma Group plc, a public quoted provider of pharmaceutical products designed to improve the outcomes and recovery for surgical patients. Prior to Acacia Pharma Group plc, Christine served as CFO and then non-executive Director of AIM-listed Electrical Geodesics, Inc., which was acquired by Philips NV in 2017. Other CFO and finance leadership roles include Optos plc, BTG plc (former FTSE250 constituent), Oxagen Limited and Celltech Chiroscience Group plc, having started her life-sciences career as Financial Controller of Medeva plc.

Christine has previously served as chair of the audit committee at e-therapeutics plc, an AIM listed technology based drug discovery platform from 2017 to February 2020 and at Provalis plc, a quoted healthcare business from 2000 to 2005.

Christine is currently a non-Executive Director of Fertility Focus Limited (since 2013) and Futurenova Limited (since 2017), a provider of antimicrobial cases for iPads and iPhones.

Christine is a chartered accountant and holds a degree in Mathematics from the University of Durham.

Andrew Duff, Chairman of Elementis, said:

"I am delighted that Christine is joining the Elementis Board. Christine is a proven and commercial CFO and brings strong experience of innovation and the commercialisation of technology to our Board"

The Company confirms that there are no other matters requiring disclosure pursuant to LR 9.6.13R (1) to (6) in respect of the appointment.

Laura Higgins

Group Company Secretary

020 7067 2999

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAUVVBRRUURAAA

(END) Dow Jones Newswires

October 16, 2020 02:00 ET (06:00 GMT)